Developments and opportunities through the gamechanger e-prescription

E-Prescription Study 22/23

E Rezept Studie 22 23 1920 1080

The highlights of the E-Prescription Study 22/23

  • E-prescription roadmap: Presentation of the Gematik roadmap and the current status quo in Germany
  • Market forecasts: The pharmacy and pharmaceutical industry up to 2030 in the areas of online sales and number of on-site pharmacies
  • Expertstatements: Exclusive interviews with renowned big names in the pharmaceutical industry - What do they think about the e-prescription?
  • Outlook: The future of e-prescribing in Germany and internationally - What can we learn from other countries?

The following download is a document in German language.

Your direct link to download

Your direct link to the Plus Member download

The e-prescription gamechanger has the potential to fundamentally change the pharmaceutical and pharmacy market as we know it today. Today, the market has more players than ever before and everyone wants to be optimally positioned for the launch of the e-prescription in order to have a chance at part of the expected sales potential. The online pharmacy market in particular has been eagerly anticipating the launch of the e-prescription for a long time. By 2030, major market shifts in favor of online retail are expected due to the major convenience factor, increasing acceptance of e-health, and greater cross-selling potential for the Rx and OTC segments. Since on average more than 90% of Rx online customers also order OTC drugs, online growth in the Rx sector is expected to lead to an increase in additional sales and thus a growing OTC sector. Also expected is an acceleration of the closure of on-site pharmacies, which has been progressing for years. By 2030, another 2,000-5,000 pharmacies may have closed in Germany.

With the E-Prescription Study 2022, Smile AI gives the turbulent events surrounding e-prescription a structured overview for the industry and places what is happening in the pharmaceutical market. First, the current e-prescription roadmap of Gematik is presented. Then, the authors shed light on current developments and future prospects of the e-prescription and calculate forecasts for the pharmacy and pharmaceutical market. In addition, exclusive expert statements from Shop-Apotheke, Zur Rose Group and gesund.de, among others, bring the perspectives of strong industry players into the study. Successful e-prescription launches in other countries are also examined in detail.

Contents of the study:

  • Gematik's e-prescription roadmap & status quo
  • Market forecasts: The pharmacy and pharmaceutical industry up to 2030
  • Expert statements: Exclusive interviews with renowned industry leaders
  • The future of e-prescription in Germany and internationally

The following download is a document in German language.

    To the Download

    Go to Plus Member Download

    Excerpts from the study

      Amazon Studie 23 28 03 23 1
      Amazon Studie 23 28 03 23 2
      Amazon Studie 23 28 03 23 6
      Amazon Studie 23 28 03 23 13
      Amazon Studie 23 28 03 23 22
      Kim tmp

      You want more information about this topic?

      Then contact Kim Lander, Head of E-Commerce & Business Development:

      Mail: kim.lander@smileai.de
      Mobil: +491771946883
      Are we connected on LinkedIn yet?

      or feel free to contact our team.

      Contact the Smile AI team

      Smile AI GmbH
      Sonnenstraße 14
      D-80331 München
      Telefon +49 89 242156500

      info@smileai.de